Skip to content
Phoenix Biotechnology, IncPhoenix Biotechnology, Inc
  • Home
  • About Us
    • Company
    • Management Team
    • Boards Of Directors
    • Scientific Advisory Board
  • Therapy Focus
    • Therapy Focus
    • Viral Diseases
    • Cancer
    • Neurodegenerative Diseases
  • Product Development
    • Products in Development
    • PBI-05204
    • PBI-01207
    • PBI-04711
  • Safety
  • Resources
  • Contact us
Oleander

Phoenix Biotechnology executes a fifth amendment to its Sponsored Research Agreement with M. D. Anderson Cancer Center.

Posted on September 2010June 2022 by Carlos Torres
06
Sep
This entry was posted in Oleander. Bookmark the permalink.
Phoenix raises >$3,000,000 from angel investors.
Phase I Clinical Trial of PBI-05204 successfully completed at M. D. Anderson Cancer Center.
Copyright 2023 © Phoenix Biotechnology, Inc. All Rights Reserved. | Terms of Use | Privacy Policy | Cookies Policy
  • Home
  • About Us
    • Company
    • Management Team
    • Boards Of Directors
    • Scientific Advisory Board
  • Therapy Focus
    • Therapy Focus
    • Viral Diseases
    • Cancer
    • Neurodegenerative Diseases
  • Product Development
    • Products in Development
    • PBI-05204
    • PBI-01207
    • PBI-04711
  • Safety
  • Resources
  • Contact us